First of all, the principle of two specific drugs, BRII- 196 and BRII- 198, is that these drugs will bind with the spike protein on the surface of COVID-19, preventing the spike protein from binding with human cells, thus achieving therapeutic effects. This specific medicine is my first medicine with independent intellectual property rights. This medicine was jointly developed by Tsinghua University and Shenzhen Third People's Hospital. At present, within 28 days of clinical trial, no one died in the drug group and 9 patients died in the placebo group. This shows the curative effect and great role of this specific medicine.
Secondly, no specific drugs causing adverse reactions have been used. In the clinical trial of drugs, the most worrying thing is that there will be adverse reactions, because once adverse reactions occur, the experiment may fail, but there are no adverse reactions in BRII- 196 and BRII- 198, and the current cure rate has reached an astonishing 100%. According to this trend, these two drugs are likely to become COVID-19's disease.
Finally, although we have developed the specific drugs of BRII- 196 and BRII- 198, we still need COVID-19 vaccine for protection. Because the specific drugs are still in the experimental stage, there is some uncertainty, so vaccination as soon as possible will have a basic guarantee for your health. If you build an extra defense line, COVID-19 will be farther away from us.
If you have any suggestions, please leave a comment below.